- SOHM, a generic drug manufacturing and distributing innovator, announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its ABBIE platform
- In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure
- SOHM’s management is optimistic about the collaboration and is confident that this is but the first step toward deepening new lab operations
- It also marks a significant milestone, as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits
SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, just announced its development collaboration with the University of Arizona Center for Innovation (“UACI”) for the advancement of its revolutionary ABBIE platform. This marks a significant milestone for SOHM, notably as it anticipates monetizing ABBIE off-the-shelf, non-viral gene editing kits through licensing opportunities as early as 2024 (https://ibn.fm/ZM4JH).
UACI expressed optimism in the arrangement, citing their confidence in ABBIE thriving through the program.
“We are delighted to assist SOHM and the development of ABBIE technology. UACI offers comprehensive support, including SBIR grant assistance, access to core research facilities, award opportunities, and investor networking,” noted Eric Smith, UACI’s Executive Director.
“Our Good Laboratory Practice (‘GLP’) facilities provide an ideal environment for technology growth, from conceptualization to clinical application. We are confident that ABBIE will thrive through our program,” he added.
In the arrangement, SOHM will establish offices and a wet lab bench, taking advantage of UACI’s robust and specialized infrastructure and a best-practice environment with certified GLP. It is confident that going with UACI would help fast-track development, ultimately allowing it to achieve its 2024 goal of taking the technology to market.
ABBIE, SOHM’s flagship offering, is a platform for non-viral gene editing technology that enables the rapid introduction of genes of interest while offering same-day screening. Given its potential, SOHM looks to develop and deploy non-viral gene-editing kits that will be developed into cell-based therapies, biologics, and diagnostics, ultimately allowing it to tap into the global biotechnology kit market, which is estimated to post a 10.9% CAGR between 2023 and 2030.
Industry experts have lauded non-viral gene-editing platforms, noting that they are at the forefront of research and development in genetics. In addition, they have highlighted their potential to treat genetic diseases while advancing biological research. More importantly, they have noted that non-viral gene-editing methods have shown potential in eliminating concerns related to immune responses, insertional mutagenesis associated with viral vectors, safety, and efficiency, as associated with current alternatives in the market.
SOHM’s management is optimistic about the collaboration and is confident that this is the first step toward deepening new lab operations.
“Having experienced the university’s world-class research facilities firsthand, I am confident in the success of ABBIE under this collaboration,” noted Dr. David Aguilar, SOHM’s COO.
“UACI has supported the company’s development. We recognize that this relationship will only deepen with the new lab operations,” he added.
For more information, visit the company’s website at www.SOHM.com.
NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN